Plasma ctDNA analysis allows non-invasive monitoring of tumour response.
Detecting de novo mutants through ctDNA may offer insights into tumour evolution.
Detecting ctDNA after radical therapy may improve stratification.
Mutant cfDNA in other body fluids may increase sensitivity to detect rare mutations.